Metabolomics with LC-QTOF-MS permits the prediction of disease stage in aortic abdominal aneurysm based on plasma metabolic fingerprint

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Ciborowski, Michal ^a,b   Teul, Joanna ^a,b   Martin Ventura, Jose Luis ^c,d   Egido, Jesús ^c,d   Barbas, Coral ^a  

^a UNIVERSIDAD SAN PABLO CEU   (Spain)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^c 28400 Madrid   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLCARNITINE; CHOLESTEROL; GUANIDINOSUCCINIC ACID; LYSOPHOSPHOLIPID; NITRIC OXIDE; SPHINGOLIPID; BIOLOGICAL MARKER; GUANIDINE DERIVATIVE; SUCCINIC ACID DERIVATIVE;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DEVELOPMENT; DISEASE CLASSIFICATION; DISEASE COURSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY QUADRUPOLE TIME OF FLIGHT TANDEM MASS SPECTROMETRY; HUMAN; LARGE ABDOMINAL AORTA ANEURYSM; MEDICAL PROCEDURES; METABOLITE; METABOLOMICS; PARTIAL LEAST SQUARE DISCRIMINATION ANALYSIS; PLASMA METABOLIC FINGERPRINTING; PREDICTION AND FORECASTING; REGRESSION ANALYSIS; SMALL ABDOMINAL AORTA ANEURYSM; STAGING; STATISTICAL ANALYSIS; VASODILATATION; AORTA; CHEMISTRY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFLAMMATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; QUALITY CONTROL; STATISTICAL MODEL;

AORTA; AORTIC ANEURYSM, ABDOMINAL; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; FEMALE; GUANIDINES; HUMANS; INFLAMMATION; LYSOPHOSPHOLIPIDS; MALE; MASS SPECTROMETRY; METABOLOMICS; MODELS, STATISTICAL; QUALITY CONTROL; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SUCCINATES;

EID: 84857527060     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031982     Document Type: Article

References (31)

1. Miyake T, Morishita R, (2009) Pharmacological treatment of abdominal aortic aneurysm. Cardiovasc Res 83: 436-443.
2. Shimizu K, Mitchell R, Libby P, (2006) Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 26: 987-994.
3. Touat Z, Ollivier V, Dai J, Huisse M, Bezeaud A, et al. (2006) Renewal of mural thrombus releases plasma markers and is involved in aortic abdominal aneurysm evolution. Am J Pathol 168: 1022-1030.
4. Moll FL, Powell JT, Fraedrich G, Verzini F, Haulon S, et al. (2011) Management of abdominal aortic aneurysms clinical practice guidelines of the European society for vascular surgery. Eur J Vasc Endovasc Surg 41 (Suppl 1): S1-S58.
5. Levin DC, Rao VM, Parker L, Frangos AJ, Sunshine JH, (2009) Endovascular repair vs open surgical repair of abdominal aortic aneurysms: comparative utilization trends from 2001 to 2006. J Am Coll Radiol 6: 506-509.
6. Klink A, Hyafil F, Rudd J, Faries P, Fuster V, et al. (2011) Diagnostic and therapeutic strategies for small abdominal aortic aneurysms. Nat Rev Cardiol 8: 338-347.
7. Michel JB, Martin-Ventura JL, Egido J, Sakalihasan N, Treska V, et al. (2011) Novel aspects of the pathogenesis of aneurysms of the abdominal aorta in humans. Cardiovasc Res 90: 18-27.
8. Mosorin M, Niemelä E, Heikkinen J, Lahtinen J, Tiozzo V, et al. (2008) The use of statins and fate of small abdominal aortic aneurysms. Interact Cardiovasc Thorac Surg 7: 578-581.
9. Krishna SM, Dear AE, Norman PE, Golledge J, (2010) Genetic and epigenetic mechanisms and their possible role in abdominal aortic aneurysm. Atherosclerosis 212: 16-29.
10. Martinez-Pinna R, Ramos-Mozo P, Madrigal-Matute J, Blanco-Colio LM, Lopez JA, et al. (2011) Identification of peroxiredoxin-1 as a novel biomarker of abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 31: 935-943.
11. Gamberi T, Puglia M, Guidi F, Magherini F, Bini L, et al. (2011) A proteomic approach to identify plasma proteins in patients with abdominal aortic aneurysm. Mol Biosyst 7: 2855-2862.
12. Shulaev V, (2006) Metabolomics technology and bioinformatics. Brief Bioinform 7: 128-139.
13. Ciborowski M, Martin-Ventura JL, Meilhac O, Michel JB, Ruperez FJ, et al. (2011) Metabolites Secreted by Human Atherothrombotic Aneurysms Revealed through a Metabolomic Approach. J Proteome Res 10: 1374-1382.
14. Gika H, Macpherson E, Theodoridis G, Wilson I, (2008) Evaluation of the repeatability of ultra-performance liquid chromatography-TOF-MS for global metabolic profiling of human urine samples. J Chromatogr B Analyt Technol Biomed Life Sci 871: 299-305.
15. Rubingh CM, Bijlsma S, Derks E, Bobeldijk I, Verheij ER, et al. (2006) Assessing the performance of statistical validation tools for megavariate metabolomics data. Metabolomics 2: 53-61.
16. Milne S, Ivanova P, Forrester J, Alex Brown H, (2006) Lipidomics: an analysis of cellular lipids by ESI-MS. Methods 39: 92-103.
17. Aoyagi K, Shahrzad S, Iida S, Tomida C, Hirayama A, et al. (2001) Role of nitric oxide in the synthesis of guanidinosuccinic acid, an activator of the N-methyl-D-aspartate receptor. Kidney Int Suppl 78 pp. S93-96.
18. Zhang F, Jia Z, Gao P, Kong H, Li X, et al. (2009) Metabonomics study of atherosclerosis rats by ultra fast liquid chromatography coupled with ion trap-time of flight mass spectrometry. Talanta 79: 836-844.
19. Sayed-Ahmed MM, Khattab MM, Gad MZ, Mostafa N, (2001) L-carnitine prevents the progression of atherosclerotic lesions in hypercholesterolaemic rabbits. Pharmacol Res 44: 235-242.
20. Arsenian MA, (1997) Carnitine and its derivatives in cardiovascular disease. Prog Cardiovasc Dis 40: 265-286.
21. Van Veldhoven PP, Mannaerts GP, Declercq P, Baes M, (2000) Do sphingoid bases interact with the peroxisome proliferator activated receptor [alpha] (PPAR-[alpha])? Cellular Signalling 12: 475-479.
22. Tsuji K, Satoh S, Mitsutake S, Murakami I, Park J-J, et al. (2009) Evaluation of synthetic sphingolipid analogs as ligands for peroxisome proliferator-activated receptors. Bioorganic & Medicinal Chemistry Letters 19: 1643-1646.
23. van Raalte DH, Li M, Pritchard PH, Wasan KM, (2004) Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm Res 21: 1531-1538.
24. Zandbergen F, Plutzky J, (2007) PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta 1771: 972-982.
25. Pyper SR, Viswakarma N, Yu S, Reddy JK, (2010) PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal 8: e002.
26. Duan SZ, Usher MG, Mortensen RM, (2008) Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ Res 102: 283-294.
27. Hamblin M, Chang L, Zhang H, Yang K, Zhang J, et al. (2010) Vascular smooth muscle cell peroxisome proliferator-activated receptor-γ deletion promotes abdominal aortic aneurysms. Journal of vascular surgery: official publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, North American Chapter 52: 984-993.
28. Tosaka M, Okajima F, Hashiba Y, Saito N, Nagano T, et al. (2001) Sphingosine 1-phosphate contracts canine basilar arteries in vitro and in vivo: possible role in pathogenesis of cerebral vasospasm. Stroke 32: 2913-2919.
29. Golledge J, Mallat Z, Tedgui A, Norman PE, (2011) Serum secreted phospholipase A2 is associated with abdominal aortic aneurysm presence but not progression. Atherosclerosis 216: 458-460.
30. Gilmour RS, Mitchell MD, (2001) Nuclear lipid signaling: novel role of eicosanoids. Exp Biol Med (Maywood) 226: 1-4.
31. Hurt-Camejo E, Camejo G, Peilot H, Oorni K, Kovanen P, (2001) Phospholipase A2 in Vascular Disease. Circ Res 89: 298-304.